Moffitt PSOC Here we focus on two deeply interconnected physical science questions: How do we study, quantify, integrate, and model the complexity of cancer biology and treatment across multiple length and time scales that form the tumor ecology? and Can the evolutionary dynamics of therapeutic resistance be exploited through dynamic spatio-temporal models to optimize treatments and improve the lives of patients with cancer? We propose that cancer must be investigated and treated as a complex adaptive systems in which the underlying first principles are Darwinian. We view intratumoral evolution as a dynamical interaction between environmental selection forces and tumor adaptive strategies to maximize fitness. A critical property of cancer complex system is that it is open and thus can be perturbed by host response and iatrogenic interventions. Thus, the multi-scale (e.g. molecular, cellular and tissue scales) spatio-temporal variations within and between cancers (i.e. the ecology of cancer) is dependent in large part on the open components of the system such as alterations in blood flow that affect local environmental conditions and subsequent cellular adaptive strategies. Similarly, the Darwinian response to therapy will vary within each habitat within the tumor ecology and must be understood to design consistently effective therapies. We approach these questions in two different ways: In project 1 we focus on fundamental principles - the cancer cell evolutionary dynamics and molecular mechanisms that permit adaptation to host-generated perturbations including blood flow and treatment strategies. Here the focus will be on sophisticated in-vitro and in-vivo experimental methods integrated with Darwinian-based mathematical models. A key deliverable from Project 1 is identification of novel therapeutic strategies that can exploit these evolutionary dynamics and molecular mechanism to improve clinical therapy. In Project 2 we will focus on developing computational models that use first principles and available clinical data to: 1. understand the patient-specific dynamics that govern response and resistance and 2. develop computational models that predict the outcomes of different therapies (e.g. multidrug chemotherapy, immunotherapy, and hormone therapy ) in individual patients. In the longer term our goal is to increase the scope of these models to permit design of patient-specific therapy to optimize overall survival. The deliverable from Project 2, therefore, include development of methods to extract maximum amounts of information from clinically available data and development of computational models to optimize clinical therapy using often sparse dynamic data. Both Projects will interact extensively with a core focused on developing computational models and applying sophisticated analytic methods to extract maximum knowledge from available molecular, pathological, and radiological clinical data.
PSOC We propose the complicated components and interactions that form a cancer must be viewed as a complex dynamical system. To understand cancer and its treatment, we must learn from successful approaches to complex systems pioneered in the physical sciences. This will require a multidisciplinary approach combining optimal data acquisition, application of Darwinian first principles, and development of sophisticated computational models.
|Subramanian, Hemachander; Gatenby, Robert A (2018) Evolutionary advantage of directional symmetry breaking in self-replicating polymers. J Theor Biol 446:128-136|
|Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963|
|Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :|
|Shah, Seema; Brock, Ethan J; Ji, Kyungmin et al. (2018) Ras and Rap1: A tale of two GTPases. Semin Cancer Biol :|
|Gallaher, Jill A; Enriquez-Navas, Pedro M; Luddy, Kimberly A et al. (2018) Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. Cancer Res 78:2127-2139|
|Yagawa, Yohsuke; Robertson-Tessi, Mark; Zhou, Susan L et al. (2017) Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. Sci Rep 7:15996|
|Picco, Noemi; Gatenby, Robert A; Anderson, Alexander R A (2017) Stem Cell Plasticity and Niche Dynamics in Cancer Progression. IEEE Trans Biomed Eng 64:528-537|
|Avnet, Sofia; Di Pompo, Gemma; Chano, Tokuhiro et al. (2017) Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-?B activation. Int J Cancer 140:1331-1345|
|Emmons, Michael F; Anreddy, Nagaraju; Cuevas, Javier et al. (2017) MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Sci Rep 7:2685|
|Zhao, Xiaohong; Lwin, Tint; Silva, Ariosto et al. (2017) Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun 8:14920|
Showing the most recent 10 out of 22 publications